A new insight in chimeric antigen receptor-engineered T cells for cancer immunotherapy

Therapeutic Potential of T Cell Chimeric Antigen Receptors (CARs) in Cancer Treatment: Counteracting Off-Tumor Toxicities for Safe CAR T Cell Therapy

(2016) Gideon Gross et al.   Annual Review of Pharmacology and Toxicology

Programming of donor T cells using allogeneic  -like ligand 4-positive dendritic cells to reduce GVHD in mice

(2016) K. Mochizuki et al.   BLOOD

A Receptor for All Occasions

(2016) Darrell J. Irvine   CELL

Precision Tumor Recognition by T Cells With Combinatorial Antigen-Sensing Circuits

(2016) Kole T. Roybal et al.   CELL

Engineering Customized Cell Sensing and Response Behaviors Using Synthetic Notch Receptors

(2016) Leonardo Morsut et al.   CELL

Engineered CAR T Cells Targeting the Cancer-Associated Tn-Glycoform of the Membrane Mucin MUC1 Control Adenocarcinoma

(2016) Avery D. Posey et al.   IMMUNITY

Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy

(2016) Yongxian Hu et al.   Journal of Hematology & Oncology

Versatile strategy for controlling the specificity and activity of engineered T cells

(2016) Jennifer S. Y. Ma et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies

(2016) David T. Rodgers et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors

(2016) Daniel T. Harris et al.   TRENDS IN PHARMACOLOGICAL SCIENCES

Design of chimeric antigen receptors with integrated controllable transient functions

(2016) Alexandre Juillerat et al.   Scientific Reports

CD19-targeted chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia

(2015) S. L. Maude et al.   BLOOD

Inducible caspase-9 suicide gene controls adverse effects from alloreplete T cells after haploidentical stem cell transplantation

(2015) X. Zhou et al.   BLOOD

Structural Design of Engineered Costimulation Determines Tumor Rejection Kinetics and Persistence of CAR T Cells

(2015) Zeguo Zhao et al.   CANCER CELL

Chimeric Antigen Receptor Engineering: A Right Step in the Evolution of Adoptive Cellular Immunotherapy

(2015) Jose A. Figueroa et al.   INTERNATIONAL REVIEWS OF IMMUNOLOGY

Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

(2015) David M. Barrett et al.   JOURNAL OF IMMUNOLOGY

Redirection of Genetically Engineered CAR-T Cells Using Bifunctional Small Molecules

(2015) Min Soo Kim et al.   JOURNAL OF THE AMERICAN CHEMICAL SOCIETY

T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial

(2015) Daniel W Lee et al.   LANCET

An Inducible Caspase-9 Suicide Gene to Improve the Safety of Therapy Using Human Induced Pluripotent Stem Cells

(2015) Shigeki Yagyu et al.   MOLECULAR THERAPY

CAR-T field booms as next-generation platforms attract big players

(2015) Chris Morrison   NATURE BIOTECHNOLOGY

Heparanase promotes tumor infiltration and antitumor activity of CAR-redirected T lymphocytes

(2015) Ignazio Caruana et al.   NATURE MEDICINE

Adoptive cell transfer as personalized immunotherapy for human cancer

(2015) S. A. Rosenberg et al.   SCIENCE

Remote control of therapeutic T cells through a small molecule-gated chimeric receptor

(2015) C.-Y. Wu et al.   SCIENCE

Anti-CD20/CD3 T cell–dependent bispecific antibody for the treatment of B cell malignancies

(2015) Liping L. Sun et al.   Science Translational Medicine

Engineering CAR-T cells: Design concepts

(2015) Shivani Srivastava et al.   TRENDS IN IMMUNOLOGY

IL-12 secreting tumor-targeted chimeric antigen receptor T cells eradicate ovarian tumorsin vivo

(2015) Mythili Koneru et al.   OncoImmunology

Antibody-modified T cells: CARs take the front seat for hematologic malignancies

(2014) M. V. Maus et al.   BLOOD

Current concepts in the diagnosis and management of cytokine release syndrome

(2014) D. W. Lee et al.   BLOOD

Engineered T cells for cancer therapy

(2014) Carl H. June et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Novel Approaches to Enhance the Specificity and Safety of Engineered T Cells

(2014) Victor D. Fedorov et al.   CANCER JOURNAL

CD28z CARs and Armored CARs

(2014) Hollie J. Pegram et al.   CANCER JOURNAL

Immune Escape Mechanisms as a Guide for Cancer Immunotherapy

(2014) G. L. Beatty et al.   CLINICAL CANCER RESEARCH

Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens

(2014) Matthew M. Gubin et al.   NATURE

Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia

(2014) Shannon L. Maude et al.   NEW ENGLAND JOURNAL OF MEDICINE

Molecular architecture of the αβ T cell receptor–CD3 complex

(2014) Michael E. Birnbaum et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Cancer Immunotherapy Based on Mutation-Specific CD4+ T Cells in a Patient with Epithelial Cancer

(2014) E. Tran et al.   SCIENCE

Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia

(2014) M. L. Davila et al.   Science Translational Medicine

The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells

(2014) Tessa Gargett et al.   Frontiers in Pharmacology

Chimeric Antigen Receptor Therapy for Cancer

(2013) David M. Barrett et al.   Annual Review of Medicine

Cytokine release syndrome in cancer immunotherapy with chimeric antigen receptor engineered T cells

(2013) Xiao-Jun Xu et al.   CANCER LETTERS

Targeting T cells to tumor cells using bispecific antibodies

(2013) Stanley R Frankel et al.   CURRENT OPINION IN CHEMICAL BIOLOGY

Adoptive T Cell Transfer for Cancer Immunotherapy in the Era of Synthetic Biology

(2013) Michael Kalos et al.   IMMUNITY

Chimeric antigen receptors for the adoptive T cell therapy of hematologic malignancies

(2013) Marco L. Davila et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Chimeric antigen receptor-engineered T cells for cancer immunotherapy: progress and challenges

(2013) Ethan Q Han et al.   Journal of Hematology & Oncology

Persistence and Efficacy of Second Generation CAR T Cell Against the LeY Antigen in Acute Myeloid Leukemia

(2013) David S. Ritchie et al.   MOLECULAR THERAPY

Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity

(2013) Cor HJ Lamers et al.   MOLECULAR THERAPY

Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia

(2013) Stephan A. Grupp et al.   NEW ENGLAND JOURNAL OF MEDICINE

Bispecific small molecule-antibody conjugate targeting prostate cancer

(2013) C. H. Kim et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

PD-1- and CTLA-4-Based Inhibitory Chimeric Antigen Receptors (iCARs) Divert Off-Target Immunotherapy Responses

(2013) V. D. Fedorov et al.   Science Translational Medicine

CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia

(2013) R. J. Brentjens et al.   Science Translational Medicine

The Basic Principles of Chimeric Antigen Receptor Design

(2013) Michel Sadelain et al.   Cancer Discovery

Tumor-targeted T cells modified to secrete IL-12 eradicate systemic tumors without need for prior conditioning

(2012) H. J. Pegram et al.   BLOOD

CD20-specific adoptive immunotherapy for lymphoma using a chimeric antigen receptor with both CD28 and 4-1BB domains: pilot clinical trial results

(2012) B. G. Till et al.   BLOOD

Engineered T cells for anti-cancer therapy

(2012) Cameron J Turtle et al.   CURRENT OPINION IN IMMUNOLOGY

Dual Targeting of ErbB2 and MUC1 in Breast Cancer Using Chimeric Antigen Receptors Engineered to Provide Complementary Signaling

(2012) Scott Wilkie et al.   JOURNAL OF CLINICAL IMMUNOLOGY

Efficacy and safety of adoptive immunotherapy using anti-CD19 chimeric antigen receptor transduced T-cells: a systematic review of phase I clinical trials

(2012) Xiao-Jun Xu et al.   LEUKEMIA & LYMPHOMA

Combinatorial antigen recognition with balanced signaling promotes selective tumor eradication by engineered T cells

(2012) Christopher C Kloss et al.   NATURE BIOTECHNOLOGY

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Seventeen-gene signature from enriched Her2/Neu mammary tumor-initiating cells predicts clinical outcome for human HER2+:ER - breast cancer

(2012) J. C. Liu et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CAR–T cells and solid tumors: tuning T cells to challenge an inveterate foe

(2012) David E. Gilham et al.   TRENDS IN MOLECULAR MEDICINE

Trial Watch

(2012) Lorenzo Galluzzi et al.   OncoImmunology

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

(2011) J. N. Kochenderfer et al.   BLOOD

Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias

(2011) R. J. Brentjens et al.   BLOOD

IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors Can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expression

(2011) M. Chmielewski et al.   CANCER RESEARCH

Cancer immunotherapy comes of age

(2011) Ira Mellman et al.   NATURE

Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy

(2011) Antonio Di Stasi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia

(2011) David L. Porter et al.   NEW ENGLAND JOURNAL OF MEDICINE

Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2

(2010) Richard A Morgan et al.   MOLECULAR THERAPY

An Inducible Caspase 9 Suicide Gene to Improve the Safety of Mesenchymal Stromal Cell Therapies

(2010) Carlos Almeida Ramos et al.   STEM CELLS

Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen

(2009) L. A. Johnson et al.   BLOOD

Graft-versus-host disease

(2009) James LM Ferrara et al.   LANCET

Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study

(2009) Fabio Ciceri et al.   LANCET ONCOLOGY

Tumor Escape Mechanism Governed by Myeloid-Derived Suppressor Cells

(2008) S. Nagaraj et al.   CANCER RESEARCH